Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsSeblewongel ASRAT, Andre LIMNANDER, Jamie ORENGO
Estimating the term…
The present disclosure provides methods for treating allergy comprising selecting a patient with an allergy and administering a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor (e.g., an anti-IL-4 receptor antibody or antigen-binding fragment thereof) in combination with a therapeutically effective amount of an agent that depletes plasma cells (e.g., an anti-BCMA/anti-CD3 bispecific antibody). In certain embodiments, a plasma cell ablating agent such as an anti-BCMA/anti-CD3 bispecific antibody ablates the plasma cells, including IgE+ plasma cells, while the IL-4/IL-13 pathway inhibitor prevents the generation of new IgE+ plasma cells, thus eliminating allergen-specific IgE in the patient.
A method of reducing or eliminating allergen-specific serum IgE in a subject, comprising:
A method of treating allergy or preventing or reducing the severity of an allergic reaction to an allergen, comprising:
A method for treating allergy or preventing or reducing the severity of an allergic reaction to an allergen, comprising:
A method of increasing the efficacy and/or tolerability of an immunotherapy regimen in a subject having an allergy, the method comprising administering to the subject an IL-4/IL-13 pathway inhibitor and a plasma cell ablating agent prior to or concurrent with the immunotherapy regimen.
Dependencies are inferred from the claim text.